Triple Negative Breast Cancer(TNBC) Clinical Trials in Los Angeles, California
4 recruitingLos Angeles, California
Showing 1–4 of 4 trials
Recruiting
Phase 1
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1
Study of XB010 in Subjects With Solid Tumors
Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674